The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future
Tóm tắt
Peritoneal metastasis (PM) is often regarded as a less frequent pattern of spread; however, collectively across all spectra of primary tumors, the consequences of PM impact a large population of patients annually. Unlike other modes of metastasis, symptoms at presentation or during the treatment course are common, representing an additional challenge in the management of PM. Early efforts with chemotherapy and incomplete surgical interventions transiently improved symptoms, but durable symptom control and survival extension were rare, which established a perspective of treatment futility for PM through most of the 20th century. Notably, the continued development of better systemic therapy combinations, optimization of cytoreductive surgery (CRS), and rigorous investigation of combining regional therapy—specifically hyperthermic intraperitoneal chemotherapy—with CRS, have resulted in more effective multimodal treatment options for patients with PM. In this article, the authors provide a comprehensive review of the data establishing the contemporary approach for tumors with a high frequency of PM, including appendix, colorectal, mesothelioma, and gastric cancers. The authors also explore the emerging role of adding hyperthermic intraperitoneal chemotherapy to the well established paradigm of CRS and systemic therapy for advanced ovarian cancer, as well as the recent clinical trials identifying the efficacy of poly(adenosine diphosphate ribose) polymerase maintenance therapy. Finally, recent data are included that explore the role of precision medicine technology in PM management that, in the future, may help further improve patient selection, identify the best systemic therapy regimens, detect actionable mutations, and identify new targets for drug development.
Từ khóa
Tài liệu tham khảo
American Society of Clinical Oncology (ASCO) Cancer.Net. Mesothelioma: Statistics. ASCO; 2021. Accessed February 14 2022.cancer.net/cancer‐types/mesothelioma/statistics
Abbasi SY, 2011, Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes, Gastrointest Cancer Res., 4, 122
Hernandez DL, 2020, Peritoneal metastasis of cholangiocarcinoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at the Instituto Nacional de Cancerologia, Colombia, Cureus., 12, e6697
Spratt JS, 1980, Clinical delivery system for intraperitoneal hyperthermic chemotherapy, Cancer Res., 40, 256
Meigs JV, 1934, Tumors of the Female Pelvic Organs, The Macmillan Company
Griffiths CT, 1979, Role of cytoreductive surgical treatment in the management of advanced ovarian cancer, Cancer Treat Rep., 63, 235
Dedrick RL, 1978, Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer, Cancer Treat Rep., 62, 1
Pretorius RG, 1981, Comparison of the iv and ip routes of administration of cisplatin in dogs, Cancer Treat Rep., 65, 1055
Sugarbaker PH, 1985, Prospective, randomized trial of intravenous versus intraperitoneal 5‐fluorouracil in patients with advanced primary colon or rectal cancer, Surgery., 98, 414
Jacquet P, 1996, Current methodologies for clinical assessment of patients with peritoneal carcinomatosis, J Exp Clin Cancer Res., 15, 49
Ang CSP, 2018, Genomic landscape of appendiceal neoplasms. JCO Precis, Oncol.
Hughes KS, 1986, Resection of the liver for colorectal carcinoma metastases: a multi‐institutional study of patterns of recurrence, Surgery., 100, 278
Rovers KP, 2019, Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open‐label, parallel‐group, phase II‐III, randomised, superiority study (CAIRO6), BMC Cancer., 19, 390, 10.1186/s12885-019-5545-0
Yonemura Y, 2012, Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer, Int J Surg Oncol., 2012, 148420
Yonemura Y, 2001, Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study, Hepatogastroenterology., 48, 1776